Scryb Reports 2026 AGM Results and Welcomes Veteran Capital Markets and Finance Directors
Toronto, Ontario--(Newsfile Corp. - April 1, 2026) - Scryb Inc. (CSE: SCYB) ("Scryb" or the "Company") is pleased to announce the results of its Annual General Meeting of shareholders (the "AGM") held on March 31, 2026. All resolutions presented at the AGM received overwhelming shareholder support, with more than 99% of votes cast in favour. This strong approval reflects shareholder confidence in the Company's management team, leadership, refreshed strategy, and long-
Biotechnologies, Soins de santé et hôpitaux, Santé
2026-04-01 7:06 AM EDT | NorthPalm Capital Corp.
Resverlogix Corp. Provides Bi-Weekly MCTO Status Update
Calgary, Alberta--(Newsfile Corp. - March 31, 2026) - Resverlogix Corp. (TSX: RVX) ("Resverlogix" or the "Company") is providing an update on the management cease trade order ("MCTO") application it made to the Alberta Securities Commission (the "ASC") under National Policy 12-203 - Management Cease Trade Orders ("NP 12-203"). The application remains under review, and no decision has yet been made by the ASC. The Company announced on March 17, 2026 (the "Original Announcement") that
Technologies, Biotechnologies, Soins de santé et hôpitaux
2026-03-31 7:09 PM EDT | Resverlogix Corp.
Dr. Christina Rahm Named One of MSN's "Top 10 Trailblazing Women in 2026"
Franklin, Tennessee--(Newsfile Corp. - March 31, 2026) - Dr. Christina Rahm, a recognized leader in science and innovation, has been selected as one of "MSN's Top 10 Trailblazing Women in 2026," a prestigious honor spotlighting women whose work is reshaping industries and driving meaningful impact across communities. The recognition appears in MSN's feature highlighting women at the forefront of change this year. "I'm truly honored to be featured in MSN's "Top 10 Trailbl
Biotechnologies, Aliments / boissons, Santé
2026-03-31 6:03 PM EDT | DRC Ventures
BioHarvest Sciences Reports Fourth Quarter and Full-Year 2025 Financial Results
British Columbia and Rehovot, Israel--(Newsfile Corp. - March 31, 2026) - BioHarvest Sciences Inc.
Biotechnologies, Pharmaceutique, Santé
2026-03-31 4:02 PM EDT | BioHarvest Sciences Inc.
BioHarvest Sciences Announces First-Ever Successful Stable Cell Culture Development of Rare Fragrance-Producing Plant Using Proprietary Botanical Synthesis Platform
British Columbia and Rehovot, Israel--(Newsfile Corp. - March 31, 2026) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a leader in Botanical Synthesis technology and sustainable plant-based molecule development, today announced that its CDMO division has successfully completed Stage 1 of a multi-stage development program for a rare scent-producing plant used in the global fragrance industry. The program is being conducted under a contract sig
Biotechnologies, Pharmaceutique, Santé
2026-03-31 8:00 AM EDT | BioHarvest Sciences Inc.
OS Therapies Completes Submission of Biomarker & Clinical Data for U.S. FDA Pre-BLA Meeting, Reports Full Year 2025 Financial Results and Provides Business Update
December 2025 Type C Meeting confirmed immune biomarkers suitability to establish surrogate clinical efficacy that could support BLA under Accelerated Approval Pathway Pre-specified clinical outcomes data correlates with Immune biomarker signature Company positioned to review completed Phase 2b clinical & biomarker data and confirmatory Phase 3 trial protocol with U.S. FDA, EMA and U.K. MHRA in 2Q/26
2026-03-31 7:40 AM EDT | OS Therapies
Telo Genomics Announces Appointment of John Farlinger as CEO and Chairman
Vancouver, British Columbia--(Newsfile Corp. - March 31, 2026) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo Genomics"), a leader in the development of diagnostic and prognostic tests for human disease through the analysis of chromosomal telomeres, has appointed John Farlinger, currently chair of the Company's audit committee, as chief executive officer and chairman. In connection with Mr. Farlinger's appointment, the Company and Mr. Farlinger have entered i
2026-03-31 7:00 AM EDT | Telo Genomics Corp.
Therma Bright Signs New Strategic Customer, Horizon Health, Currently Selling over 35,000 Compression Products Annually
Toronto, Ontario--(Newsfile Corp. - March 31, 2026) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX0) ("Therma" or the "Company"), a developer and investment partner specializing in advanced diagnostic and medical device technologies, announces it has secured a strategic commercial order for an initial
Technologies, Biotechnologies, Santé
2026-03-31 6:30 AM EDT | Therma Bright Inc.
Phio Pharmaceuticals Announces Agreement with U.S. cGMP Manufacturing Source for Drug Product, PH-762
King of Prussia, Pennsylvania--(Newsfile Corp. - March 30, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that it has entered into a cGMP drug product manufacturing services agreement with a U.S. manufacturer for clinical supply for future clinical trials. The company will manufacture Phio's lead compo
Biotechnologies, Soins de santé et hôpitaux, Pharmaceutique, Santé
2026-03-30 7:00 AM EDT | Phio Pharmaceuticals Corp.
TempraMed Signs LOI for Distribution Agreement in Panama, Expanding Central American Exposure
Vancouver, British Columbia--(Newsfile Corp. - March 30, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) ("TempraMed" or the "Company"), a medical-technology innovator transforming how temperature-sensitive medications are stored and managed, is pleased to announce that it has signed a non-binding letter of intent ("LOI"), dated March 22, 2026, with TEM Consulting International S.A. ("TEM") a leading healthcare logistics and consultancy com
Technologies, Biotechnologies, Pharmaceutique, Santé
2026-03-30 7:00 AM EDT | TempraMed Technologies Ltd.
PreveCeutical Medical Inc. Appoints Raj S. Pruthi, MD, MHA, FACS, as Director
Vancouver, British Columbia--(Newsfile Corp. - March 30, 2026) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H0) ("PreveCeutical" or the "Company"), a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature-identical products, is pleased to announce the appointment of Dr. Raj S. Pruthi, MD, MHA, FACS, to its Board of Directors. Dr. Pruthi is an accomplished physician-scientist and executi
Biotechnologies, Pharmaceutique, Santé
2026-03-30 3:00 AM EDT | PreveCeutical Medical Inc.
InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Compliance
Vancouver, British Columbia--(Newsfile Corp. - March 27, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company developing a pipeline of disease-modifying small molecule drug candidates targeting CB1 and CB2 receptors, today announced the Company received a written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") dated March 27, 2026, notifying it that the closing bid price of the Company's
Biotechnologies, Pharmaceutique
2026-03-27 5:05 PM EDT | InMed Pharmaceuticals
Neural Therapeutics Announces Amendment to SIO Agreement, Concurrent Financing Terms, Shareholder Meeting Date and RSU Grant
Toronto, Ontario--(Newsfile Corp. - March 27, 2026) - Neural Therapeutics Inc. (CSE: NURL) (FSE: HANF) ("Neural" or the "Company") announces that it has entered into a second amending agreement (the "SIO Amendment") to its strategic investment and option agreement dated May 26, 2025, as previously amended (the "SIO Agreement"), with CWE European Holdings Inc. ("CWE"), operating as Hanf.com, one o
Biotechnologies, Pharmaceutique, Santé, Psychédéliques
2026-03-27 7:30 AM EDT | Neural Therapeutics Inc.
OS Therapies Granted Meetings with U.S. FDA, U.K. MHRA, EMA and Australian Therapeutic Goods Administration to Review Global Confirmatory Phase 3 Trial for OST-HER2 in Metastatic Osteosarcoma
New York, New York--(Newsfile Corp. -
2026-03-27 6:00 AM EDT | OS Therapies
PharmaTher Introduces PatchPrint(TM) With Provisional Patent Filing and Commercialization Strategy for Microneedle Patches
Toronto, Ontario--(Newsfile Corp. - March 26, 2026) - PharmaTher Holdings Ltd. (CSE: PHRM) (OTCQB: PHRRF) ("PharmaTher" or the "Company"), a specialty pharmaceutical company, announced i
Biotechnologies, Pharmaceutique
2026-03-26 8:00 AM EDT | PharmaTher Holdings Ltd.
BioHarvest Sciences Announces that VINIA is Now the No.1 Resveratrol Polyphenol Brand in the United States
British Columbia and Rehovot, Israel--(Newsfile Corp. - March 26, 2026) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a biotechnology company pioneering its proprietary Botanical Synthesis™ platform, today announced that its VINIA® brand has achieved the position of the #1 Resveratrol Polyphenol Nutraceutical Brand in the United States*. VINIA's leadership position is driven by its clinically demonstrate
Biotechnologies, Pharmaceutique, Santé
2026-03-26 7:30 AM EDT | BioHarvest Sciences Inc.
Kiora Pharmaceuticals Reports Fourth-Quarter and Full-Year 2025 Results; Company Advances Retinal Disease Pipeline with Two Active Phase 2 Clinical Trials
Encinitas, California--(Newsfile Corp. - March 25, 2026) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced financial results for the fourth quarter and full year ended December 31, 2025, and provided a year-end business update on its pipeline of small molecules for the treatment of retinal diseases. Key fourth-quarter, full-year 2025, and recent corporate highlights include: Advanced KIO-301 from regulatory clearance to patient
Biotechnologies, Pharmaceutique
2026-03-25 7:00 AM EDT | Kiora Pharmaceuticals, Inc.
OS Therapies Granted EMA's Advanced Therapy Medicinal Product (ATMP) Designation for OST-HER2 in the Treatment of Pulmonary Recurrence in Resected Osteosarcoma
New York, New York--(Newsfile Corp. - March 25, 2026) - OS Therapies, Inc
2026-03-25 6:00 AM EDT | OS Therapies
TempraMed Strengthens Global Intellectual Property Position with Granted Chinese Patent for Newest Product, VIVI Box
Highlights Chinese patent officially granted by CNIPA on March 17, 2026 Covers core innovations underpinning TempraMed's VIVI Box™ multi-medication storage platform expected to market end of 2026 Strengthens the Company's intellectual property position in one of the world's largest healthcare and consumer markets Supports commercialization strategy and strategic engag
Technologies, Biotechnologies, Pharmaceutique, Santé
2026-03-24 7:00 AM EDT | TempraMed Technologies Ltd.
Sernova Biotherapeutics Announces Close of Non-Brokered Private Placement Financing
Ontario and Boston, Massachusetts--(Newsfile Corp. - March 24, 2026) - Sernova Biotherapeutics (TSX: SVA) (OTC Pink: SEOVF) (FSE: PSH0) ("Sernova" or the "Company"), a leading regenerative medicine company focused on developing its Cell Pouch Bio-hybrid Organ as a functional cure for type 1 diabetes (T1D), today announced the closing of its non-brokered private placement financing that has secured total gross proceeds of $2.1 million. The Company issued 13,762,659 units in
2026-03-24 7:00 AM EDT | Sernova Biotherapeutics